

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

AGENCY AGREEMENT WITH WUHAN ADV. DENTAL CO., LTD.*

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 28 April 2015, Essex Medipharma entered into the Agency Agreement with Adv. Dental pursuant to which, among other things, Essex Medipharma is appointed by Adv. Dental as its exclusive sales agent for Carisolv Products in certain designated areas of China.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 28 April 2015, 珠海億勝醫藥有限公司 (Essex Medipharma (Zhuhai) Co., Ltd.*) (“**Essex Medipharma**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred to as the “**Group**”) entered into an agency agreement (“**Agency Agreement**”) with 武漢佻典生物科技有限公司 (Wuhan Adv. Dental Co., Ltd.*) (“**Adv. Dental**”). Pursuant to the Agency Agreement, among other things, Essex Medipharma is appointed by Adv. Dental as its exclusive sales agent for products of Carisolv®佻典®齶齒微創祛腐技術系統 (“**Carisolv Products**”) in certain designated areas of Mainland China (excluding Taiwan, Hong

Kong and Macau) (“**China**”). Carisolv is a system which uses minimally invasive techniques to treat dental caries. Carisolv Products include Carisolv®**佶典**®minimally invasive dental caries removal gel (齲齒微創祛腐凝膠) and Caritool®**佶典**®minimally invasive dental caries removal tools (牙科微創祛腐工具). The Agency Agreement is for a term from 1 May 2015 to 31 December 2019. Provided that Essex Medipharma has complied with its obligations under the Agency Agreement, the term shall be automatically extended for three years to 31 December 2022 unless otherwise terminated by either party.

The establishment of business relationship with Adv. Dental is synergetic to the Group’s products, Beifuji and Beifuxin, for advancing the Group’s business expansion in stomatology department.

The Group is principally engaged in the manufacturing, selling, marketing and distribution of biopharmaceutical products.

By order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 28 April 2015

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

* *For identification purpose only*